HighLife
HighLife Medical develops a transcatheter mitral-valve replacement system designed to treat patients with severe mitral regurgitation without open-heart surgery.
€80MFinancing round
LeadSP
Sofinnova Partners
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
- Rounds participated in
- 6
- Confirmed lead rounds
- 1 5 roles undisclosed
- New companies
- 6 First participation on record · 0 follow-on
- Funding in participating rounds
- $577M 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in this selectionBionyra Pharma
Bionyra Pharma develops biologic therapies for severe immunological and inflammatory diseases.
$165MSeries A
Role not disclosedCellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedSignadori Bio
Develops in vivo engineered monocyte immunotherapy to treat solid tumours in preclinical stage
€11.1MSeed+
Role not disclosedNeurent Medical
Neurent Medical develops NEUROMARK, a minimally invasive radiofrequency treatment for chronic rhinitis.
€62.5MSeries C
Role not disclosedBrightHeart
BrightHeart develops AI software for prenatal ultrasound and fetal-heart screening.
€11MSeries A
Role not disclosed